510(k) Report

510(k) · Cleared

Cleared

EliA M2 Immunoassay

K181556510(k) TraditionalCleared Jul 13, 201830-day reviewClass II21 CFR 866.5090

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Phadia AB · DBM Antimitochondrial Antibody, Indirect Immunofluorescent, Antigen, Control

Cleared on Jul 13, 2018 as substantially equivalent to K141375 (Phadia US, Inc., 2015) after a 30-day review. Its family tree reaches back 2 generations to 2005.

Decided
Jul 13, 2018
Review
30 days
Class
Class II
Product code
DBM
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to K052262 (2005). No later device cites it as a predicate yet.

  1. Root · 2 generations backK052262 Quanta Lite M2 EP (MIT3) ElisaInova Diagnostics, Inc. · 2005
  2. 1 generation backK141375 Elia M2; Immunoassay, Positive Control 100, Positive Control 250Phadia US, Inc. · 2015
  3. This deviceK181556 EliA M2 ImmunoassayPhadia AB · 2018
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K052262Quanta Lite M2 EP (MIT3) ElisaInova Diagnostics, Inc.2005—
−1K141375Elia M2; Immunoassay, Positive Control 100, Positive Control 250Phadia US, Inc.2015—
0 (this device)K181556EliA M2 ImmunoassayPhadia AB2018—
FIG. 1 — Lineage of K181556, 2005–2018Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in DBM? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K141375Elia M2; Immunoassay, Positive Control 100, Positive Control 250
Summary page 6
…2500/5000 006_A.6 510k Decision Summary Input A.6-3 I. Device Description: The method-specific reagents are identical with K141375 (EliA M2 on Phadia 250), but are filled in containers specific for the Phadia 2500/5000 instrument. Each device consists…
Phadia US, Inc.2015—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 13 years and passes through 3 companies; a new generation was cleared every 9.3 years on median.
  • None of the 2 ancestors has a recall.

How does its category compare?

All DBM devices

DBM Antimitochondrial Antibody, Indirect Immunofluorescent, Antigen, Control: FDA decisions, review times, recalls and adverse event reports over 20 years. 2018, this device’s year, is highlighted.

FDA decisions per year · DBM

1in 2018

2010: 12015: 12017: 22018: 1
2007high 2 (2017) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · DBM

Too few DBM 510(k)s in any year since 2007 to give a median.

Recalls per year · DBM

1in 2008

2008: 1
2007high 1 (2008) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · DBM

1in 2018

2018: 1
2007high 1 (2018) · low 0 (2007)2025

MAUDE reports naming product code DBM, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—10
20090—00
20101—00
20110—00
20120—00
20130—00
20140—00
20151—00
20160—00
20172—00
20181—01
20190—00
20200—00
20210—00
20220—00
20230—00
20240—00
20250—00
20260—0—

What is it indicated for?

EliA M2 is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to M2 in human serum and plasma (Li-heparin, EDTA) to aid in the clinical diagnosis of primary biliary cirrhosis in conjunction with other laboratory and clinical findings. EliA M2 uses the EliA IgG method on the instrument Phadia 2500/5000.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K181556: EliA M2 Immunoassay.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K181556

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026